Idogen’s financial contribution from Horizon 2020 now finalizes with a publication

Idogen AB (publ) today announces that an article about our IDO 8 program, is now published on the European Commission’s CORDIS website.

The article summarizes the results of the financial contribution of about 2.86 MEUR (about 29 MSEK) granted to Idogen by Horizon 2020, EU’s framework of research and innovation, in May 2017. The purpose of the grant was to develop the company’s tolerogenic cell therapy for treating severe hemophilia patients who have developed neutralizing antibodies against their treatment with factor VIII.

”The grant from EU’s Horizon 2020 have really contributed to make our technology platform ready for the manufacturing of cell therapy for recently initiated  clinical trial, with current quality requirements” says Christina Herder, acting CEO.

The article can be read here https://cordis.europa.eu/article/id/442422-targeted-cell-therapies-suppress-undesirable-immune-responses

For further information, please contact:

Christina Herder, Acting CEO, Idogen AB

Tel: +46 70 374 71 56

E-mail: christina.herder@idogen.com

Certified Advisor:
Vator

The information was submitted for publication through the agency of the contact persons set out above on November 14, 2022 at 15:16 CET.

Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced program, IDO 8 – now in clinical phase – is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies.  For these hemophiliac patients, there is significant medical need for restoring the clinical effects of their treatment with factor VIII. This is a unique market positioning that over the long term could replace immune tolerance induction (ITI) treatments, with significant market potential. The planned IDO 8 clinical trial will validate the company’s technology platform and facilitate a range of other applications in fields such as organ transplants (IDO T)  and autoimmune diseases (IDO AID). More information about Idogen is available via https://www.idogen.com